EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tunable Intranasal Polymersome Nanocarriers Triggered Olanzapine Brain Delivery and Improved In Vivo Antipsychotic Activity

Ahmed A Katamesh iD, Hend Mohamed Abdel-Bar iD, Rania Mahafdeh iD, Mohammed Khaled Bin Break iD, Shimaa M Hassoun iD, Gehad M Subaiea iD, Mostafa E El-Naggar iD, Khaled Almansour iD, Hadel A Abo El-Enin iD, Heba A Yassin

Pharmaceutics · 23.06.2025 · 17 (7) · 811

DOI: 10.3390/pharmaceutics17070811 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 23.06.2025. Verfasst von Ahmed A Katamesh und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, College of Pharmacy, University of Ha'il, Ha'il 81442, Saudi Arabia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Ha'il, Saudi Arabia, Scientific Research Deanship at the University of Ha’il, Saudi Arabia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Olanzapine (Ola) is a second-generation antipsychotic with clinical utility limited by poor brain bioavailability due to blood–brain barrier restriction, hepatic first-pass metabolism, and systemic side effects. This study aimed to develop and optimize a novel intranasal polymersome-based nanocarrier (PolyOla) to enhance brain targeting, therapeutic efficacy, and safety of Ola.

Methods

PolyOla was prepared using poloxamer 401 and optimized through a Box–Behnken Design to minimize particle size and maximize entrapment (EE%) and loading efficiency (LE%). The formulation was characterized by size, morphology, drug release, and serum stability. In vivo studies in adult male Sprague-Dawley rats assessed pharmacokinetics (plasma and brain concentrations), pharmacodynamic efficacy in a ketamine-induced schizophrenia model, and systemic safety markers including metabolic, hepatic, and testicular oxidative stress indicators.

Results

Optimized PolyOla exhibited a particle size of 78.3 ± 4.5 nm, high EE% (91.36 ± 3.55%), and sustained in vitro drug release. It remained stable in serum for 24 h. Intranasal administration significantly improved brain delivery of Ola, achieving a 2.7-fold increase in Cmax and a 5.7-fold increase in AUC compared to oral dosing. The brain Tmax was 15 min, with high drug-targeting efficiency (DTE% = 365.38%), confirming efficient nose-to-brain transport. PolyOla-treated rats showed superior antipsychotic performance, reduced extrapyramidal symptoms, and improved systemic safety evidenced by mitigated weight gain, glycemic control, normalized liver enzymes, and reduced oxidative stress.

Conclusions

PolyOla offers a safe and effective intranasal delivery platform for Ola, enabling targeted brain delivery and improved management of schizophrenia with reduced peripheral toxicity.

Schlagwörter

Stichwörter der Autor:innen

antipsychoticbrain targetingintranasalolanzapinepolymersomes

Autor:innen und Institutionen

  • Department of Pharmaceutics, College of Pharmacy, University of Ha'il, Ha'il 81442, Saudi Arabia.
  • Department of Pharmaceutics, Faculty of Pharmacy, University of Sadat City, Menoufia 32897, Egypt.
  • Department of Clinical Pharmacy and Therapeutics, Faculty of Pharmacy, Jadara University, Irbid 21110, Jordan.
  • Department of Pharmaceutical Chemistry, College of Pharmacy, University of Ha'il, Ha'il 81442, Saudi Arabia.
  • Medical and Diagnostic Research Centre, University of Ha'il, Ha'il 55473, Saudi Arabia.
  • Department of Pharmacology, College of Pharmacy, University of Ha'il, Ha'il 81442, Saudi Arabia.

ORCID-Profile: Ahmed A Katamesh, Hend Mohamed Abdel-Bar, Rania Mahafdeh, Mohammed Khaled Bin Break, Shimaa M Hassoun, Gehad M Subaiea, Mostafa E El-Naggar, Khaled Almansour, Hadel A Abo El-Enin

Förderung

  • University of Ha'il, Saudi Arabia
  • Scientific Research Deanship at the University of Ha’il, Saudi Arabia

Zitieren

APA

Katamesh, A. A., Abdel-Bar, H. M., Mahafdeh, R., Bin Break, M. K., Hassoun, S. M., Subaiea, G. M., El-Naggar, M. E., Almansour, K., Abo El-Enin, H. A., & Yassin, H. A. (2025). Tunable Intranasal Polymersome Nanocarriers Triggered Olanzapine Brain Delivery and Improved In Vivo Antipsychotic Activity. Pharmaceutics, 17(7), 811. https://doi.org/10.3390/pharmaceutics17070811

Vancouver

Katamesh AA, Abdel-Bar HM, Mahafdeh R, Bin Break MK, Hassoun SM, Subaiea GM, et al. Tunable Intranasal Polymersome Nanocarriers Triggered Olanzapine Brain Delivery and Improved In Vivo Antipsychotic Activity. Pharmaceutics. 2025;17(7):811. doi:10.3390/pharmaceutics17070811

BibTeX
@article{Katamesh2025,
  author = {Katamesh, Ahmed A and Abdel-Bar, Hend Mohamed and Mahafdeh, Rania and Bin Break, Mohammed Khaled and Hassoun, Shimaa M and Subaiea, Gehad M and El-Naggar, Mostafa E and Almansour, Khaled and Abo El-Enin, Hadel A and Yassin, Heba A},
  title = {Tunable Intranasal Polymersome Nanocarriers Triggered Olanzapine Brain Delivery and Improved In Vivo Antipsychotic Activity},
  journal = {Pharmaceutics},
  year = {2025},
  volume = {17},
  number = {7},
  pages = {811},
  doi = {10.3390/pharmaceutics17070811}
}
Kostenlos starten →